Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.53 |
| ▸ | ECE1 | P42892 | 6/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361028 | 1.00 | UTS2R (0.55) | UTS2RACEPRMT1GHSRIL23R | |
| SCHEMBL29938488 | 0.96 | GHSR (0.59) | UTS2RGHSRIL23R | |
| SCHEMBL29937863 | 0.96 | GHSR (0.59) | UTS2RGHSRIL23R | |
| SCHEMBL31514545 | 0.95 | GHSR (0.59) | UTS2RGHSRIL23R | |
| SCHEMBL30602952 | 0.95 | GHSR (0.59) | UTS2RGHSRIL23R | |
| SCHEMBL30898976 | 0.94 | ACE (0.55) | UTS2RACEGHSRECE1 | |
| SCHEMBL31632618 | 0.94 | ACE (0.55) | UTS2RACEGHSRECE1 | |
| SCHEMBL29938179 | 0.93 | IL23R (0.61) | UTS2RGHSRIL23R | |
| SCHEMBL29564504 | 0.93 | GHSR (0.56) | UTS2RPRMT1GHSRIL23R | |
| SCHEMBL29564832 | 0.93 | GHSR (0.56) | UTS2RPRMT1GHSRIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | claimed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| EP-4514405-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2025-03-05 | — | — | EP | disclosed |
| EP-4380629-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2024-06-12 | — | — | EP | disclosed |
| CN-110678198-B | Targeting modules to immune cells expressing universal chimeric antigen receptor and their use in the treatment of cancer, infections and autoimmune disorders | 阿文塞勒欧洲有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117164726-A | Targeting module for immune cells expressing universal chimeric antigen receptor and uses thereof | 阿文塞勒欧洲有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023209122-A1 | COMBINATION TREATMENT OF SMALL-CELL LUNG CANCER | ITM Isotope Technologies Munich SE (DE) | 2023-11-02 | — | — | WO | disclosed |
| EP-4251213-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM Solucin GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | disclosed |
| EP-4065176-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotope Technologies Munich SE (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022112323-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111800-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096103-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | UTS2R 2879/4885ACE 2759/4885PRMT1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.